BluefitMD: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.bluefitmd.com/, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “BluefitMD” on the pictured label, suggesting BluefitMD is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

3. 3

   ““Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)””

4. 4

   ““Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)””

5. 5

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

bluefitmd.com returned a live storefront on 2026-08-09 advertising "Personalized GLP-1 Treatments As low as $75/mo*" with the footnote "*With a 12-month package", alongside testosterone, NAD+, methylene blue and sermorelin categories and compounded semaglutide and tirzepatide product pages. That is a check of whether the site is up and what it advertises; it is not a check of anything the letter alleges.

Read the two findings together and they answer each other. The copy said the vial holds the same active ingredient as Ozempic; the photograph of that vial said BluefitMD made it — and FDA's position is that BluefitMD did not. So the page told a shopper both what is inside and who put it there, and the second answer was wrong, which is a reason to be careful with the first. That pairing is what makes this the most instructive letter in the collection: a name on a label is not a marketing claim, it is an answer to "who is accountable", and it was answered by a company that, on FDA's account, was the seller rather than the compounder. The site's advertised price today is the other half of the lesson — "As low as $75/mo", with the asterisk resolving to "*With a 12-month package". A headline rate that requires twelve months of commitment is a different product from a monthly one, and the figure a reader remembers is the one before the asterisk. None of this is a finding about the drugs themselves; FDA made no claim here about quality, contents or manufacturing, and the letter has not been closed out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence BluefitMD failed to respond.